Blog
RSS FeedPosted by Michael Wonder on 04 Sep 2023
ACT calls for "productivity focus" for PHARMAC
3 September 2023 - The policy was discussed on Q+A with Jack Tame by new candidate Todd Stephenson, who has ...
Posted by Michael Wonder on 04 Sep 2023
PHARMAC funds first treatment for primary progressive multiple sclerosis
4 September 2023 - PHARMAC has confirmed it is widening access to ocrelizumab (Ocrevus) as the first funded treatment for ...
Posted by Michael Wonder on 01 Sep 2023
Emergent BioSolutions’ Narcan nasal spray launches over the counter making it possible for everyone to help save a life from an opioid overdose emergency
30 August 2023 - Narcan nasal spray will be the first, life-saving emergency medicine for opioid overdose available on shelves beginning ...
Posted by Michael Wonder on 31 Aug 2023
New Zealand Pharmaceutical Schedule - 1 September 2023
1 September 2023 - The September 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Aug 2023
Schedule of Pharmaceutical Benefits - 1 September 2023
1 September 2023 - The September 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Aug 2023
Mitsubishi Tanabe Pharma Canada announces that company's oral treatment formulation for amyotrophic lateral sclerosis has been added to the provincial drug plans in New Brunswick and Nova Scotia
29 August 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension (edaravone) is now covered under the New ...
Posted by Michael Wonder on 27 Aug 2023
PHARMAC announcement of more blood cancer medicines welcomed
27 August 2023 - Myeloma New Zealand is welcoming Pharmac's announcement of more blood cancer medicines, but says the country is ...
Posted by Michael Wonder on 24 Aug 2023
PHARMAC seeking bids from suppliers for multiple myeloma treatments
24 August 2023 - PHARMAC is seeking bids from suppliers for two medicines, lenalidomide and pomalidomide, for use in the ...
Posted by Michael Wonder on 23 Aug 2023
PHARMAC confirms transition to a trastuzumab biosimilar and widens access to other types of cancer
23 August 2023 - PHARMAC is transitioning to a trastuzumab biosimilar, Herzuma, from the currently funded brand, Herceptin, as a result ...
Posted by Michael Wonder on 22 Aug 2023
CDC, pharmacies try to speed up Covid vaccine program for the uninsured
21 August 2023 - The timing gap prompted concerns from public health experts, who fear that it would further complicate the ...
Posted by Michael Wonder on 22 Aug 2023
Suggestions Nat's cancer drug funding promise has put PHARMAC in a difficult position
22 August 2023 - It's being suggested National's cancer drug funding promise has put PHARMAC in a difficult position. ...
Posted by Michael Wonder on 21 Aug 2023
Patients get antsy amid protracted price bargaining for Spinraza, Evrysdi
21 August 2023 - Drug price negotiations for two spinal muscular atrophy drugs --Spinraza (nusinersen sodium) and Evrysdi (risdiplam) – ...
Posted by Michael Wonder on 21 Aug 2023
National to roll back free prescription fees to pay for 13 cancer treatments
21 August 2023 - The National Party wants to bring back the $5 prescription fee for those who can afford ...
Posted by Michael Wonder on 19 Aug 2023
Quebec becomes the first province to reimburse Minjuvi (tafasitamab) in combination with lenalidomide for patients with diffuse large B-cell lymphoma
17 August 2023 - This is the first public listing since Minjuvi was approved with conditions by Health Canada in ...
Posted by Michael Wonder on 17 Aug 2023
Amicus Therapeutics announces approval and launch of new Pompe disease therapy in the United Kingdom
15 August 2023 - Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) approved for adults living with late-onset Pompe disease in Great Britain. ...